Introduction
The National Neisseria Network (NNN), Australia comprises reference laboratories in each State and Territory that report data on susceptibilities for an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics are penicillin, ceftriaxone, azithromycin and ciprofloxacin and represent current or potential agents used for the treatment of gonorrhoea. Azithromycin combined with ceftriaxone is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.
Results
A summary of the proportion of isolates with decreased susceptibility to ceftriaxone (MIC 0.06-0.25 mg/L), and the proportion resistant to azithromycin (MIC ≥1.0 mg/L), penicillin (MIC ≥1.0 mg/L), and ciprofloxacin (MIC ≥1.0 mg/L) for Quarter 3 2018 are shown in Table 1 . * Penicillin resistance includes MIC value of ≥1.0 mg/L, or penicillinase production.
Ceftriaxone
For the AGSP the category of ceftriaxone decreased susceptibility (DS) includes the MIC values 0.06-0.25 mg/L. The breakpoint for ceftriaxone resistance is yet to be determined. In the third quarter of 2018, the proportion of isolates with ceftriaxone DS in Australia was 1.55%, slightly higher than the proportion in the first and second quarters of 2018, and slightly higher than the annual proportion for 2017 ( Table 2 ). There were no isolates reported in the second or third quarters of 2018 in Australia with an MIC >0.125 mg/L. Of note, there were two isolates exhibited DS to ceftriaxone (MIC = 0.06mg/L) and resistance to azithromycin, one from Victoria, and one from urban/rural Western Australia. One of these isolates, from urban Western Australia, was also resistant to penicillin, but sensitive to ciprofloxacin.
The national trend of isolates with ceftriaxone decreased susceptibility (MIC 0.06 and ≥0.125 mg/L) since 2012 is shown in Table 2 . A summary of ceftriaxone DS strains that were penicillin and ciprofloxacin resistant, or isolated from extra genital sites (rectal and pharyngeal) for Quarter 3, 2018 by state or territory, and by sex (male/female) are shown in Table 3 . 
Azithromycin
In the third quarter of 2018, the proportion of isolates with resistance to azithromycin (MIC ≥1.0 mg/L) in Australia was 7.1%, higher than the proportion reported nationally in the first and second quarters of 2018, but lower than for 2017 (9.3%), and three times the level reported in Australia for 2013-2015 (2.1%-2.6%) (Table 4 ).(1) Globally there have been increasing reports of azithromycin resistance in N. gonorrhoeae. (2) In quarter 3 2018, most states reported isolates with resistance to azithromycin, with the exception of Northern Territory and remote Western Australia. The states that reported an increase in the number and proportion of N. gonorrhoeae isolates with resistance to azithromycin when compared with the previous quarter of 2018 were New South Wales, Australian Capital Territory, Tasmania, and South Australia. There were two isolates that exhibited resistance to azithromycin and DS to ceftriaxone (MIC = 0.064mg/L). One of these isolates, from urban Western Australia, was also resistant to penicillin, but sensitive to ciprofloxacin. There were no isolates in this quarter that exhibited high level resistance to azithromycin (MIC ≥256 mg/L).
The national trend of azithromycin resistance in isolates since 2012 is shown in 
